Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors
Molecules · 2025
DOI: 10.3390/molecules30122508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Shi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Drug Discovery and Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, China. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Hydroxamic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Natural Science Foundation, Guangxi Science and Technology Major Program, Guangxi Key Laboratory of Drug Discovery and Optimization.
Abstract (Originalsprache)
In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, a series of imidazothiazole-based hydroxamic acid derivatives were designed based on the pharmacophore fusion strategy and evaluated as potent IDO1 and HDAC6 dual inhibitors. Among these inhibitors, the most potent compound 3-(4-Bromophenyl)-N-{4-[(7-(hydroxyamino)-7-oxoheptyl)amino]phenyl}imidazo[2,1-b]thiazole-5-carboxamide (10e) showed considerable IDO1 inhibitory activity and a good selectivity profile for HDAC6 over the other HDAC isoforms. The intracellular inhibition of HDAC6 by 10e was validated by Western blot analysis. Docking studies illustrated that the possible binding modes of compound 10e interacted with IDO1 and HDAC6. Moreover, compound 10e was found to arrest the cell cycle at the G2/M phase in HCT-116 cells. In particular, compound 10e also exhibited potent in vivo antitumor efficacy in CT26 tumor-bearing BALB/c mice models, with no significant toxicity. Collectively, this work provides a promising lead compound that serves as IDO1/HDAC6 dual inhibitor for the development of novel antitumor agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Drug Discovery and Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
- Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
- Key Laboratory of Medical Biotechnology and Translational Medicine, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
Förderung
- Guangxi Natural Science Foundation
- Guangxi Science and Technology Major Program
- Guangxi Key Laboratory of Drug Discovery and Optimization
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources
- Guilin Scientific Research and Technology Development Plan Project
- the College Students' Innovative Entrepreneurial Training Plan Program
- College Students’ Innovative Entrepreneurial Training Plan Program
Zitieren
APA
Zhang, S., Wang, Y. F., Lu, H. R., Yang, X. Q., Zhang, Y., Ma, X. L., & Huang, R. Z. (2025). Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors. Molecules. https://doi.org/10.3390/molecules30122508
Vancouver
Zhang S, Wang YF, Lu HR, Yang XQ, Zhang Y, Ma XL, et al. Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors. Molecules. 2025. doi:10.3390/molecules30122508
BibTeX
@article{Zhang2025,
author = {Zhang, Shi and Wang, Yan-Fei and Lu, Hai-Rui and Yang, Xue-Qin and Zhang, Ye and Ma, Xian-Li and Huang, Ri-Zhen},
title = {Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30122508}
}
EUVIMED